Tumor Necrosis Factor Receptor Superfamily Member 5 ? Pipeline Review, H1?2018

Posted by Vansh Rao on February 7th, 2018

Tumor Necrosis Factor Receptor Superfamily Member 5 B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40 pipeline Target constitutes close to 22 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes. The latest report Tumor Necrosis Factor Receptor Superfamily Member 5 Pipeline Review, H1 2018, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 5 B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.

Tumor Necrosis Factor Receptor Superfamily Member 5 B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40 Tumor Necrosis Factor Receptor Superfamily Member 5 is a member of the TNFreceptor superfamily. This protein is a receptor on antigenpresenting cells of the immune system and is essential for mediating a broad variety of immune and inflammatory responses including T celldependent immunoglobulin class switching, memory B cell development, and germinal center formation. The interaction of this receptor and its ligand is found to be necessary for amyloidbetainduced microglial activation, and thus is thought to be an early event in Alzheimer disease pathogenesis. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 7, 4 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Gastrointestinal, Genito Urinary System And Sex Hormones, Central Nervous System, Hormonal Disorders and Metabolic Disorders which include indications Solid Tumor, Melanoma, NonSmall Cell Lung Cancer, Pancreatic Cancer, Gastric Cancer, Kidney Transplant Rejection, Ovarian Cancer, Bladder Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Crohns Disease Regional Enteritis, Lymphoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Bile Duct Cancer Cholangiocarcinoma, Central Nervous System CNS Tumor, Diffuse Large BCell Lymphoma, Esophageal Cancer, Focal Segmental Glomerulosclerosis FSGS, Follicular Lymphoma, Gastroesophageal GE Junction Carcinomas, Graves Diseases, Head And Neck Cancer, Heart Transplant Rejection, Hepatic Liver Tumor, Hodgkin Lymphoma BCell Hodgkin Lymphoma, Hyperthyroidism, Kidney Cancer Renal Cell Cancer, Liver Transplant Rejection, Lupus Nephritis, Membranous Glomerulonephritis, Metastatic Adenocarcinoma of The Pancreas, Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Transitional Urothelial Tract Cancer, Multiple Sclerosis, Myasthenia Gravis, Pancreatic Ductal Adenocarcinoma, Pancreatic Islet Transplant Rejection, Pediatric Diffuse Intrinsic Pontine Glioma, Primary Biliary Cirrhosis, Prostate Cancer, Rheumatoid Arthritis, Sicca Syndrome Sjogren, Type 1 Diabetes Juvenile Diabetes and Ulcerative Colitis.

Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.

Scope

The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 5 B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40
The report reviews Tumor Necrosis Factor Receptor Superfamily Member 5 B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40 targeted therapeutics and enlists all their major and minor projects
The report assesses Tumor Necrosis Factor Receptor Superfamily Member 5 B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 5 B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40 targeted therapeutics

For more information, please visit @ https://www.24marketreports.com/life-sciences/tumor-necrosis-factor-receptor-superfamily-member-5-b-cell-surface-antigen-cd40-or-bp50-or-cdw40-or-cd40l-receptor-or-tnfrsf5-or-cd40pipeline-review-h1-2018-market-53

Table Of Content-

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tumor Necrosis Factor Receptor Superfamily Member 5 B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40 Overview
Tumor Necrosis Factor Receptor Superfamily Member 5 B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40 Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tumor Necrosis Factor Receptor Superfamily Member 5 B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40 Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tumor Necrosis Factor Receptor Superfamily Member 5 B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40 Companies Involved in Therapeutics Development

Contact Us-
 New York City Zone 01,
 United States,
 Int’l: (+1) 646 781 7170,
 UK(Toll free): +44 800 088 5734,
 help@24marketreports.com